IM Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
299 Washington St Ste A, Woburn, Massach...Phone Number
(303) 544-2104Website
www.imtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About IM Therapeutics
Aurimi is a biotechnology company focused on developing genetically-targeted oral HLA inhibitors to address autoimmune diseases, particularly Type 1 diabetes. Their lead product, AMT-002, is designed to selectively block autoantigen responses in patients with the HLA-DQ8 genetic allele, aiming to provide a safe and effective oral therapy. The company is preparing for a landmark Phase 2 study to treat newly-diagnosed Type 1 diabetes patients, having already demonstrated favorable safety and pharmacokinetics in Phase 1 trials. Aurimi's leadership team comprises experts in immunology and diabetes treatment, positioning the company to make significant advancements in the field of autoimmune disease management.Explore more
Popular SearchesIM TherapeuticsImmunomolecular Therapeutics IncIM Therapeutics IncImtherapeuticsImmunomolecular Therapeutics LLCSIC Code 28,283NAICS Code 32,325Show moreIM Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IM Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if IM Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once IM Therapeutics has new funding data
IM Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if IM Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when IM Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if IM Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at IM Therapeutics
Earning: See what the market has to say on IM Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined IM Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to IM Therapeutics
Compare insights from companies similar to IM Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IM Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IM Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IM Therapeutics.
IM Therapeutics Tech Stack
A closer look at the technologies used by IM Therapeutics
IM Therapeutics News & Media
IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D, to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021. IM Therapeutics is a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases. Dr. Gottlieb’s talk, entitled “Genetically Selected Patients for Targeted ImmuneIM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology. Dr. Alleva is an immunologist with deep experience in R&D in autoimmunity and infectious disease spanning 22 years and across early-stage biotech, foundations, and clinical-stage bIM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors
WOBURN, Mass.--(BUSINESS WIRE)-- #HLAtarget--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants knownIM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study
WOBURN, Mass.--(BUSINESS WIRE)-- #Autoimmunedisease--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable autoimmune disorder that affects nearly 1.6 million Americans, and who also have a specific genetic trait known as HLA-DQ8, present in about 60
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IM Therapeutics
Sign Up For FreeTo access detailed company insights
Aurimi is a biotechnology company focused on developing genetically-targeted oral HLA inhibitors to address autoimmune diseases, particularly Type 1 diabetes. Their lead product, AMT-002, is designed to selectively block autoantigen responses in patients with the HLA-DQ8 genetic allele, aiming to provide a safe and effective oral therapy. The compa... Read More
